Jag Capital Management LLC Buys 200 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Jag Capital Management LLC increased its position in IQVIA Holdings Inc. (NYSE:IQV) by 1.6% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 12,631 shares of the medical research company’s stock after buying an additional 200 shares during the quarter. Jag Capital Management LLC’s holdings in IQVIA were worth $2,482,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently made changes to their positions in IQV. Capital Performance Advisors LLP acquired a new position in shares of IQVIA in the third quarter valued at approximately $27,000. Synergy Asset Management LLC acquired a new stake in IQVIA during the 4th quarter valued at approximately $33,000. Avior Wealth Management LLC increased its position in IQVIA by 117.6% during the 3rd quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock valued at $38,000 after purchasing an additional 87 shares during the period. Assetmark Inc. increased its position in IQVIA by 612.5% during the 3rd quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock valued at $54,000 after purchasing an additional 196 shares during the period. Finally, Ashton Thomas Securities LLC acquired a new stake in IQVIA during the 3rd quarter valued at approximately $57,000. Institutional investors and hedge funds own 89.62% of the company’s stock.

Analyst Ratings Changes

A number of analysts have weighed in on the stock. StockNews.com downgraded shares of IQVIA from a “buy” rating to a “hold” rating in a research report on Thursday, November 28th. Morgan Stanley increased their target price on shares of IQVIA from $245.00 to $250.00 and gave the company an “overweight” rating in a research report on Tuesday, February 11th. Bank of America decreased their target price on shares of IQVIA from $255.00 to $235.00 and set a “buy” rating for the company in a research report on Friday, December 13th. Stifel Nicolaus reduced their price objective on shares of IQVIA from $273.00 to $261.00 and set a “buy” rating for the company in a research report on Friday, February 7th. Finally, Robert W. Baird reduced their price objective on shares of IQVIA from $212.00 to $210.00 and set a “neutral” rating for the company in a research report on Tuesday, January 21st. Four equities research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $251.22.

IQVIA Price Performance

Shares of NYSE:IQV opened at $184.67 on Tuesday. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12. The stock’s fifty day simple moving average is $198.84 and its two-hundred day simple moving average is $214.25. IQVIA Holdings Inc. has a 1-year low of $184.06 and a 1-year high of $261.73. The stock has a market cap of $32.52 billion, a PE ratio of 24.62, a price-to-earnings-growth ratio of 1.99 and a beta of 1.48.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. As a group, analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.